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Abstract 
 
Mechanisms of insulin resistance after immunosuppressive 
therapy in brown adipose tissue 
 
Post transplant diabetes mellitus (PTDM) is a metabolic syndrome that affects a large 
number of patients with chronic treatment with immunosuppressive agents (IAs).  It is known 
that IAs modulates negatively insulin sensitive-tissues such as skeletal muscle, liver and white fat. 
However, the effects of IAs on insulin action and thermogenesis in brown adipose tissue have 
not been studied. In this study we have analyzed the impact of rapamycin, cyclosporine A (CsA) 
and tacrolimus (FK506) in the insulin signaling cascade in differentiated brown adipocytes from 
rat. We found that the three compounds inhibits insulin-mediated protein kinase B (PKB/Akt) 
phosphorylation as well as glucose transporter 4 (GLUT4) translocation to the plasma 
membrane and glucose uptake, with the effect of the immunosuppressor rapamycin being more 
evident (p<0.001). Moreover, degradation of IRS-1 was only observed in rapamycin and CsA-
treated cells. Rapamycin induced an early activation of N-terminal Janus activated kinase (JNK) 
and, as a consequence, increased serine phosphorylation of insulin receptor substrate (IRS-1) at 
serine 307 residue. However, no effects of rapamycin were found in other stress kinases such as 
p38 mitogen-activated protein kinase (MAPK) or extracellular signal-regulated kinase (ERK). 
Rapamycin also inhibited basal (p<0.05) and norepinephrine-induded (p<0.05) mRNA levels of 
uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma coactivator 
1 alpha (PGC1α). Conversely, CsA and FK506 induced the opposite effect by increasing both 
UCP1 and PGC1α mRNAs. Our results have demonstrated for the first time the unique role of 
brown adipose tissue as a target of IAs suggesting that insulin resistance in BAT might 
contribute to PTDM. 
 
 
 
 
Keywords: Immunosuppressive agents, insulin resistance, post-transplant diabetes mellitus, 
brown adipose tissue 
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Resumo 
 
Mecanismos de resistência à insulina após terapia de 
imunossupressão em tecido adiposo castanho  
 
Diabetes mellitus pós-transplante (PTDM) é uma síndrome metabólica que afecta um 
grande número de doentes em tratamento crónico com agentes imunossupressores (IAs). É 
sabido que os IAs modulam negativamente tecidos sensíveis à insulina como são o músculo-
esquelético, o fígado e o tecido adiposo branco. Contudo, os efeitos dos IAs na acção da insulina 
e na termogénese no tecido adiposo castanho ainda não são conhecidos. Neste estudo, 
analisámos o impacto da rapamicina, da ciclosporina A (CsA) e tacrolimus (FK506) na cascada 
da sinalização de insulina em adipócitos castanhos diferenciados de ratos. Verificámos que os 
três compostos inibem a proteína cinase B (PKB / Akt) mediada por insulina assim como inibe a 
translocação do transportador de glucose 4 (GLUT4), sendo que o efeito da rapamicina é mais 
evidente (p<0.001). Além disso, observámos degradação de IRS-1 apenas em células tratadas 
com os compostos rapamicina e CsA. A rapamicina induziu uma activação inicial da cinase N-
terminal Janus activada (JNK) e, como consequência, aumentou a fosforilação do substrato do 
receptor de insulina 1 (IRS-1) no resíduo de serina 307. No entanto, não verificámos efeitos da 
rapamina em outras cinases de stress como a proteína cinase activada por mitógeno (MAPK) p38 
ou a cinase regulada por sinal extracelular (ERK). A rapamicina inibiu também os níveis basais 
(p<0.05) e induzidos por norepinefrina (p<0.05) de mRNA da proteína desacopladora 1 (UCP1) 
e ―peroxisome proliferator-activated receptor gamma coactivator 1 alpha‖ (PGC1α). Por outro 
lado, CsA e FK506 induziram o efeito oposto, aumentando ambos os níveis de mRNA de UCP1 
e PGC1α. Estes resultados demonstraram pela primeira vez o papel único do tecido adiposo 
castanho como sendo um alvo dos IAs, sugerindo que a resistência à insulina em BAT pode 
contribuir para a PTDM. 
 
 
 
Palavras-chave: Agentes imunossupressores, insulino-resistência, diabetes mellitus pós-
transplante, tecido adiposo castanho 
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I. Literature Review 
 
1.1. Insulin resistance and type 2 diabetes  
 
 Type 2 diabetes (T2D) is a chronic metabolic disease that has become increasingly 
common over the last decades. Each year the number of new outcomes for this epidemic disease 
continues to rise and there are about 346 million people suffering with T2D. It is predicted that 
by 2030 over 439 million people worldwide will suffer from T2D, and, therefore its 
socioeconomic impact is experienced globally (Shaw JE. et al. 2010, Zhang P. et al. 2010). T2D is 
caused by a combination of genetic and environmental factors. It begins with an impairment of 
the insulin signaling cascade in the target tissues, skeletal muscle, liver and adipose tissue leading 
to a metabolic condition known as insulin resistance. When insulin resistance develops, insulin, 
secreted by the beta-cell in the pancreas, is needed at much higher levels in order to maintain the 
normal homeostasis of glucose in the peripheral tissues. This disorder may lead to beta-cell 
failure which may culminate in the development of T2D. 
    
1.2. Immunosuppressive agents and “secondary diabetes” 
 
Immunosuppressive agents (IAs) inhibit the immune system in order to terminate an 
immune response (Subramanian S. et al., 2007). They are commonly used for prevention of 
allograft rejection and autoimmune diseases. However, in long-term treatments, secondary 
complications can be developed including osteoporosis, hypertension, dyslipidaemia, insulin 
resistance and T2D (Coutinho AE. et al., 2011).  
IAs are often used after solid organ transplantation, including kidney, heart, liver, and 
pancreas in order to prevent rejection episodes. However, previously non-diabetic subjects, 
undergoing transplantation develop post-transplant diabetes mellitus (PTDM) in response to 
immunosuppressive therapies (Hjelmesaeth J. et al., 2005). There are some contributing factors 
to the development of PTDM including increasing dose use, older age, positive family history of 
diabetes mellitus, and ethnicity (Subramanian S. et al., 2007). 
Agents commonly employed for immunosuppression include glucocorticoids such as 
prednisone and dexamethasone, calcineurin inhibitors such as cyclosporine A (CsA) and 
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tacrolimus (FK506), and mTOR inhibitors such as rapamycin (also known as sirolimus) and 
everolimus. 
 
1.2.1. Glucocorticoids as immunosuppressive agents - endogenous and 
exogenous Glucocorticoids 
 
Glucocorticoids (GCs) are used for their potent anti-inflammatory effects. Indeed, these 
agents are often used to stop undesirable immune responses like in autoimmune diseases and in 
post-transplant therapy. Endogenous GCs can modulate the immune system and shape both 
adaptive and innate immune responses (Kauh EA. et al., 2011).  
Cortisol is the main endogenous GC and the secretion of this steroid hormone secretion 
is controlled by a complex series of feedback loops. However, the principal triggers are the free-
circulating levels of cortisol, the sleep-wake cycle (diurnal variation) and corticotrophin-releasing 
hormone. Cortisol levels increase quickly in stress environments, whether physical (trauma, 
surgery, exercise), psychological (anxiety, depression), or physiological (hypoglycemia, fever) 
(Bujalska IJ. et al., 1999). However, free endogenous GCs are confined to a great percentage 
within a floating glycoprotein called corticosteroid-binding globulin (CBG) and thus, most of the 
cortisol is restricted from binding to the GC receptor, preventing its intrinsic function. 
Differently from cortisol, exogenous or synthetic GCs have low affinity for CBG and thus, this 
protein seems to play no role in insulin resistant models that had exogenous GC treatment (Qi 
D. et al., 2006). 
GC therapies occur mostly by the use of exogenous GCs, named prednisone (inactive 
form), prednisolone (active form) and dexamethasone which is known to be the most potent GC 
immunosuppressor (Kauh EA. et al., 2011). Dexamethasone is commonly used in severe 
inflammatory conditions and autoimmune disorders like rheumatoid arthritis (Hasan EA. et al., 
2009). However, because of the numerous side effects in different types of tissues, 
dexamethasone can’t be used in a full dose range or for long-term treatment periods (Kauh EA. 
et al., 2011). 
GCs can lead to secondary diabetes by the development of insulin resistance followed by 
enhanced gluconeogenesis in the liver and decreased glucose uptake and glycogen synthesis in 
skeletal muscle (Hjelmesaeth J. et al., 2005). In addition, GCs also induce degradation of proteins 
to free amino acids in the muscle, lipolysis in adipose tissue and inhibition of pancreatic insulin 
production and secretion (Subramanian S. et al. 2007; Kim JW. et al. 2012).  Moreover, treatment 
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with GCs represents the higher risk to develop PTDM with reported incidence rates up to 40% 
in renal and liver transplant recipients (Subramanian S. et al. 2007). 
GCs therapy also promote hyperlipidemia (elevated blood lipid levels) in the post-
transplant period, with incidence rates up to 60% for kidney transplants, 80% for cardiac 
transplant, and 45% for liver transplant. Evidence shows that GCs can disrupt the activity of 
several key enzymes, including increased activity of acyl coenzyme A carboxylase, fatty acid 
synthase and HMG CoA reductase, and decreased activity of lipoprotein lipase (LPL), 
contributing to the undesired effect of hiperlypidemia and dyslipidaemia (Subramanian S. et al. 
2007). 
For a long time, exogenous GCs, have been playing an important role in 
immunosuppression. In fact, prednisone and dexamethasone were the main IAs for organ 
transplantation until the introduction of new IAs such as calcineurin inhibitors, that show less 
adverse effects (Hjelmesaeth J. et al. 2005). In recent years, GCs, such as the steroid 
prednisolone, are given to patients in combination therapies with calcineurin inhibitors such as 
CsA or FK506  in order to reduce and prevent relapse of steroid use because of the serious 
health problems such as PTDM when these GCs are used chronically (Hjelmesaeth J. et al. 2005; 
Eguchi A. et al. 2010)  
Many reports show that subjects treated with these drugs have a propensity to develop 
insulin resistance and insulin signaling impairment (Sakoda H. et al. 2000; Burén J. et al. 2002) 
However, the mechanisms through which the metabolic syndrome is developed remain poorly 
understood. Dexamethasone treatment decreases insulin-stimulated glucose uptake in adipocytes 
in a time-dependent manner and these results appears to be due to depletion of insulin receptor 
substrate-1, phosphatidylinositol 3-kinase (PI3-K) and protein kinase B (PKB/Akt) (Burén J. et 
al. 2002). In addition, dexamethasone treatment has been shown to decrease p70S6K 
phosphorylation by about 50% (Burén J. et al. 2002). This protein kinase has an important role in 
insulin signaling involving the PI3-K/PKB pathway for glucose uptake and to terminate insulin 
response mechanisms (Figure 1). 
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1.2.2. Calcineurin inhibitors 
 
Calcineurin inhibitors play a major role in immunosuppressive regimens since their 
introduction in 1980 with CsA and a decade later with FK506 (Subramanian S. et al., 2007; 
Hjelmesaeth J. et al., 2005). Calcineurin is a calmodulin-dependent serine/threonine phosphatase 
that consists of a regulatory subunit, calcineurin b1 (Cnb1), and a catalytic subunit, calcineurin A 
(CnA), both of which are required for calcineurin function (Heit JJ. 2007). The calcineurin 
complex is activated by increased levels of intracellular Ca2+, leading to dephosphorylation of its 
substrates, which include the cytoplasmatic subunits of nuclear factor of activated T cells 
(NFATc) transcription complexes. NFATc proteins are then translocated into the nucleus where 
they bind sequences in target genes with partner transcription factors (NFATn) and activate 
transcription of genes (figure 2) (Heit JJ. 2007). 
 
Figure 1. Schematic ilustration of the insulin signaling cascade in adipose tissue and the action of 
both dexamethasone (orange arrows) and rapamycin (black arrows) on the IRS,PI3-K,PKB/Akt 
pathway (Adapted from Pereira MJ. et al, 2012).  
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Activation of the calcineurin/NFAT pathway in response to increased intracellular Ca2+ 
levels, results in coordination of gene expression, growth, terminal differentiation and cellular 
response to environmental cues (Heit JJ. 2007; Heit JJ. et al. 2006). In the beta-cell, 
calcineurin/NFAT signaling induces activation of insulin transcription, thereby increasing insulin 
production (Heit JJ. 2007). Of most importance, calcineurin/NFAT signaling mediates T-cell 
activation in lymphocytes through transcriptional activation of IL-2 and other important factors 
(Heit JJ. 2007). Thus, after characterization of this pathway in lymphocytes, there was the 
development of IAs such as CsA and FK506, an important step in immunssuppressive therapy 
(Heit JJ. 2007; Øzbay LA. et al. 2011). CsA and FK506 inhibit calcineurin function by binding to 
the regulatory proteins of the enzyme, cyclophilin A and 12 kDa FK506-binding protein (FKBP-
12), respectively (Heit JJ. 2007). Both drugs also inhibit the actions of prolactin, an immune 
activator, thereby providing a synergistic effect on immunomodulation (Subramanian S. et al. 
2007).  
It is known that both calcineurin inhibitors are associated with elevation in blood glucose 
levels (hyperglycemia) and blood lipid levels (hyperlipidemia), a condition that results in  
impaired beta-cell function (Subramanian S. et al. 2007; Böhmer AE. et al. 2009). Although these 
two calcineurin inhibitors have some differences in their mechanisms of action and metabolism, 
Figure 2. Representation of calcineurin/NFAT signaling pathway. Abbreviations: CnA, Calcineurin A; 
Cnb1, Calcineurin b1; CaM, calmodulin; NFATn, nuclear binding partner of NFATc proteins; P, 
phosphate group,; CsA, cyclosporine A; FK506, tacrolimus (Adapted from Heit JJ, 2007). 
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both show identical adverse effects if used for long-term periods. FK506 shows fewer side 
effects regarding lipid metabolism compared to the administration of CsA (Deleuze S. et al. 
2006). In addition, FK506 also demonstrates fewer effects on total cholesterol and low density 
lipoprotein cholesterol (LDL-C) levels, compared to CsA that showed increased levels of these 
lipid components increasing the risk of cardiovascular diseases (Deleuze S. et al. 2006). Many 
studies have been made in order to understand the mechanism by which calcineurin regulates 
insulin transcription and whether other important beta-cell factors are similarly affected by 
calcineurin inhibitors, however, much is still unclear regarding their mechanism of action. (Heit 
JJ. 2007; Böhmer AE. et al. 2009). 
 
1.2.2.1. Cyclosporine A 
 
CsA is a hydrophobic cyclic polypeptide consisting of 11 amino acids (figure 3). It has 
been widely used as an immunosuppressant in organ transplantation, as well as in the therapy of 
autoimmune disorders (Böhmer AE. et al. 2009; Wolf A. et al. 1997). Currently, CsA is 
commercially manufactured from the fungi culture Tolypocladium inflatum (Borel et al, 1974). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The use of CsA is associated with impaired glucose metabolism and PTDM in 5% to 
35% of renal transplant recipients (Subramanian S. et al. 2007). Differently from other IAs, the 
mechanism by which CsA impairs glucose metabolism appears to be mainly due to a decrease in 
insulin secretion (Subramanian S. et al. 2007; Heit JJ. 2007; Heit JJ. et al. 2006). 
Figure 3.  The structure of Cyclosporine A. Its molecular formula: C62H111 N11O12 
and molecular weight: 1202.61 g/mol. 
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CsA inhibits the production of interleukins, gamma-interferon (INF-γ) and other 
lymphokines, acting as an immunomodulator of immune and inflammatory reactions (Heit JJ. 
2007; Böhmer AE. et al. 2009). In vivo, an adverse effect is that, CsA interferes with oxidative 
stress in the rat kidney and liver by increasing lipid peroxidation, depleting the hepatic and renal 
pools of glutathione and impairing antioxidant defense system, causing toxicity in cells (Wolf A. 
et al. 1997). 
Studies performed in rats show that CsA treatment decreases the serum levels of IL-
1alpha/beta and IL-2 by treatments with either 5 or 15mg/kg/day and no significant changes 
were detected in IL-6 and INF-γ with either concentration (Böhmer AE et al. 2009). In addition, 
with a 15mg/kg/day CsA treatment, a mild hepatocellular vacuolinization with scattered cell 
infiltration was observed in the liver, but the metabolic functions were preserved (Böhmer AE et 
al. 2009). This information demonstrates that the nephrotoxicity and hepatoxicity are dependent 
of the CsA concentration and further investigation is needed to reveal the toxicity of CsA upon 
either renal or liver functions.  
Knock out studies for the regulatory subunit, Cnb1 show that this deletion decreases 
beta-cell proliferation and reduces pancreatic insulin content, resulting in diabetes-like symptoms 
(Heit JJ. et al. 2006). Thus, it is demonstrated that calcineurin plays a major role in the regulation 
of pancreatic cell growth and proliferation by controlling multiple factors involved in gene 
transcription (Heit JJ. 2007; Heit JJ. et al. 2006). 
 
1.2.2.2. Tacrolimus 
 
FK506 is a powerful macrolide immunosuppressor and selective anti-T-lymphocyte agent 
(figure 4) (Pierre E. et al., 1993). This immunosuppressive agent discovered in 1984 was isolated 
from the fungus Streptomyces tsukubaensis, and similar to CsA, it also targets calcineurin, inhibiting 
calcineurin/NFAT signaling (Thomson AW. et al. 1993).  
 
 
 
 
 
 
 
Figure 4. FK506 structure. Molecular formula: 
C44H69NO12 . Molecular weight: 804.018 g/mol. 
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The effects of CsA and FK506 on insulin signaling and beta cell growth have been 
studied in order to compare the side effects of both calcineurin inhibitors. Some studies have 
reported that FK506 is more diabetogenic than CsA and therefore the incidence of ―insulin 
dependent‖ PTDM has been reported to be higher in subjects taking FK506 (Hjelmesaeth J. et 
al. 2005). The mechanism regarding this evidence might be explained by a greater inhibition on 
the transcription of the insulin 2 gene and its release, and also a higher decrease on beta-cell 
proliferation by the calcineurin inhibitor FK506 (Hjelmesaeth J. et al. 2005; Øzbay LA. et al. 
2011, Rodriguez-Rodriguez AE. et al. 2013).  
 Regarding lipid homeostasis, recent studies show that incubation with FK506 increases 
both basal and isoproterenol-stimulated lipolysis in human subcutaneous adipocytes; an effect 
shared by other IAs such as CsA and rapamycin (Pereira MJ. et al 2013).    
 
1.2.3. mTOR inhibitors as immunosuppressors 
 
The mammalian target of rapamycin (mTOR) is part of two multiprotein complexes, 
mTORC1 (or mTOR-raptor) and mTORC2 (or mTOR-rictor), which have different roles in the 
cell (Di Paolo S. et al. 2006). These kinases are important for the insulin signaling by acting in a 
negative feedback mechanism, terminating/inhibiting insulin effects (Veilleux A. et al. 2010, Di 
Paolo S. et al. 2006).  mTORC1 acts as a cellular nutrient sensor and regulates cell growth 
through effectors such as p70S6 kinase-1 (p70S6K1) and 4E binding protein 1 (4EBP1), while 
mTOR2 controls cell survival and cytoskeleton regulation (Di Paolo S. et al. 2006).  mTORC1 
regulates other cellular effects including mitochondrial oxidative function through the 
transcription factor peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1α;) protein synthesis through activation of p70S6K effector; and autophagy in starvation 
tolerance (figure 5) (Di Paolo S. et al. 2006,  Ost A. et al. 2010). It is suggested that mTORC2 is 
insensitive to rapamycin, however, long-term treatment seems to disrupt the appropriate 
assembly of mTORC2 and its associated proteins (Sarbassov DD. et al. 2006). The mTOR 
signaling pathway can be activated by different agents such as growth factors, hormones 
(insulin), nutrients (glucose) and the cellular energy levels as well (Di Paolo S. et al. 2006). 
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mTOR inhibitors such as rapamycin (also known as sirolimus) have been extensively 
used in immunosuppressive therapy after transplantations, in more recent years. However, the 
inhibition of the mTOR signaling pathway is also associated with diverse side effects at the lipid 
and glucose metabolism levels in different tissues (Di Paolo S. et al. 2006). Some reports show 
evidence that chronic rapamycin administration causes hyperlipidemia, reduces fat mass and 
promotes glucose intolerance that can result in PTDM (Di Paolo S. et al. 2006, Houde VP. et al. 
2010). These reports are in accordance with other studies where inhibition of the mTOR 
signaling pathway blocks insulin-induced phosphorylation of insulin receptor substrate 1 (IRS-1) 
on serine and tyrosine residues, resulting in decrease insulin sensitivity (Øzbay LA. et al. 2011, Di 
Paolo S. et al. 2006 and Takano A. et al. 2001). 
The mechanism by which mTOR inhibitors affect insulin action still needs further 
investigation, but most investigators speculate that the long-term inhibition of the mTORC1 
blocks the effector p70S6 kinase impairing IRS-1 phosphorylation, thus preventing its 
degradation (Øzbay LA. et al. 2011, Di Paolo S. et al. 2006 and Takano A. et al. 2001). This leads 
to partial inhibition of mTORC2 activity which decreases activation of Akt/PKB that is 
associated in glucose transporter type 4 (GLUT4) translocation, resulting in decreased glucose 
uptake in the insulin target cells, particularly, in skeletal muscle and adipose tissue (Paolo S. et al. 
2006 and Takano A. et al. 2001). In the liver, there is evidence that chronic rapamycin treatment 
stimulates gluconeogenesis by upregulating gluconeogenic key enzymes such as 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) and thereby 
promoting insulin resistance (Houde VP. et al. 2010). Other proteins regarding gluconeogenesis 
Figure 5. Major mTOR functions: protein synthesis, protection from autophagy and mitochondrial 
function (Adapted from Öst A. et al, 2010). 
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are also upregulated such as PGC1α, forkhead box O1 (FoxO1), cAMP response element-
binding protein (CREB) and CREB-regulated transcription coactivator 2 (CRTC2). These 
alterations allow increasing plasma glucose levels and, therefore, causing glucose intolerance that 
might leads to insulin resistance (Houde VP. et al. 2010). The pathogenic effects of IAs are 
summarized on Table 1. 
 
 
Table 1 – Summary of potential pathogenic mechanism(s) of drug-induced PTDM: 
Immunosuppressive 
agent 
Proposed mechanism(s) Comments 
Glucocorticoids  
 ↓ Peripheral insulin sensitivity 
 Promote protein degradation 
to free amino acids in 
muscle, lipolysis 
 Inhibit pancreatic insulin 
production and secretion 
 ↑ Hepatic gluconeogenesis 
 
 Dose-dependent 
 Impact of complete 
withdrawal of 
chronic low-dose 
steroids unclear 
 Potential ↓ NODAT 
risk in steroid-free 
regimens 
 
Cyclosporine A 
 ↓ insulin secretion (CsA < 
FK506) 
 ↓ insulin synthesis 
 ↓ beta-cell density 
 
 Dose-dependent, 
 Diabetogenic effect 
↑ with ↑ steroid 
dose* 
 
Tacrolimus 
 ↓ insulin secretion (FK506 > 
CsA) 
 ↓ insulin synthesis 
 
 Dose-dependent, 
 Diabetogenic effect 
↑ with ↑ steroid 
dose* 
 
Rapamycin 
 ↑ Peripheral insulin resistance 
 Impair pancreatic beta-cell 
response   
 
 Diabetogenicity 
when use with CNIs 
 
Note: * Demonstrated in some but not all studies. 
Abbreviations: CsA, cyclosporine A; FK506, tacrolimus; CNIs, calcineurin 
inhibitors; ↑increased; ↓, decreased. (Pham PT. et al. 2011) 
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1.3. Adipose tissue 
 
Adipose tissue is a peripheral tissue that is mainly composed of two different subtypes: 
white adipose tissue (WAT) and brown adipose tissue (BAT).  WAT is widely distributed and it 
represents the primary site of fat metabolism and storage, whereas BAT is relatively scarce and is 
specialized in thermogenesis. White adipose tissue is composed of mostly adipocytes, surrounded 
by connective tissue that is highly vascularised and innervated; it contains macrophages, 
fibroblasts and adipocyte precursors. Brown adipose tissue is a major site for nonshivering 
thermogenesis in mammals and consisting essentially of brown adipocytes (Valverde AM. et al., 
2005). Morphologically, brown adipocytes are characterized by the presence of multiple lipid 
droplets with a high number of mitochondria (Figure 6) (Smorlesi A. et al. 2012).  We will focus 
on brown adipose tissue, since it is most relevant for the context of this work. 
 In addition to muscle and liver, adipose tissue is a relevant site of insulin action. Insulin 
resistance in adipose tissue leads to an increase in lipolysis, with subsequent release of glycerol 
and free fatty acids (FFA) into the circulation where its high availability and utilization 
contributes to the development of skeletal muscle insulin resistance, as well as to increased 
hepatic glucose production and impair beta-cell function (Foley, 1992; Yuan, M. et al., 2001).  
 
 
 
 
 
 
 
 
Figure 6: Morphology features of brown (a) and white fat cells (b). Light microscopy of mouse 
anterior subcutaneous fat depot in an area where white and brown adipose tissues are close to each other. 
(Extracted from Smorlesi A. et al., 2012. 
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1.3.1. Brown Adipose tissue 
 
BAT has its primary development during the fetal formation and is found in all mammals 
at their time of birth and also especially abundant in hibernating mammals (Gesta S. et al. 2007).  
The relevance of BAT in adult humans has been a subject of controversy for many years 
due to a great loss of phenotype and function in the first years after birth. However, after the 
(re)discovery of BAT (Cohade C. et al. 2003; Zingaretti MC. et al. 2009), the scientific 
community is now challenged to evaluate the real relevance of BAT in adult humans. 
Interestingly, the presence of BAT was revealed during the diagnosis for cancers by positron 
emission tomography / computed tomography (PET/CT). Small amounts of BAT can be found 
in the neck, in the supraclavicular and axillary regions; in the paravertebral, perirenal/adrenal, 
and in paraventral regions; and around the major vessels (the aorta and its main branches: 
carotids, subclavian, intercostals, and renal arteries) (Figure 7). BAT can also be found within 
WAT and skeletal muscles (Cypess et al. 2010, Charmaine S. Tam et al. 2012; Richard D., Picard 
F. 2011).   
  
 
 
 
 
 
 
 
 
  
 BAT has characteristically dark brown color due to the high mitochondrial content and 
an elevated number of lipid droplets in opposition to WAT, which has characteristically white 
color, with few mitochondria and with only one large lipid droplet.  When inactivated, BAT loses 
its phenotype, probably due to apoptotic phenomena and turning into the appearance of the 
Figure 7. Localization of brown adipose 
tissue in an adult lean human measured 
by emission tomography. Computed 
tomographic (CT; top) and positron 
emission tomographic (PET; with 18F-
fluorodeoxyglucose; middle) images 
from the neck and thoracic region. 
Bottom, The superimposition of the CT 
and PET scans. In the 3 panels, shown 
from left to right are a transverse slice at 
the level of the clavicles, a sagittal slice at 
the level of the spine, and a coronal slice 
of the thorax. Activated brown adipose 
tissue areas (red and green) are in the 
cervical-supraclavicular (most com-
mon), perirenal/adrenal, and 
paravertebral regions. (Extracted from 
Charmaine S. Tam et al., 2012) 
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WAT, losing its specific characteristics gradually.  Functionally, BAT is involved in the 
dissipation of energy via heat generation. This unique thermogenic capacity results from the 
expression of uncoupling protein-1 (UCP-1), a protein existing in the inner mitochondrial 
membrane, which uncouples fatty acid oxidation from ATP synthesis, allowing dissipation of 
energy from substrate oxidation as heat (Miranda S. et al., 2009).  
The development of brown adipocytes are mainly controlled by two essential 
transcriptional factors known as peroxisome proliferator-activated receptor γ (PPARγ) and 
PGC1α, which induce adipogenesis and enhance the thermogenic machinery  of brown 
adipocytes (Tontonoz P, et al. 2008). Despite the ultrastructural and metabolic morphology 
differences between BAT and WAT, it is believed that both fat tissues derive from the same 
precursors relying on the role of PPARγ during evolution and maturity of the cells (Tontonoz P, 
et al. 2008, White UA. et al. 2010). Moreover, recent data show that a specific stimulus such as 
chronic cold exposure or β-adrenergic stimulation in mice or rat induces the transdifferentiation 
of white adipose depots into brown-appearing depots in a process called ―browning‖ (Ohno H. 
et al. 2012, Smorlesi A. et al. 2012; Bonet ML. et al. 2012). The brown-like adipocytes that appear 
in classical WAT depots have been called ―brite‖ (brown-in-white) or ―beige‖ adipocytes 
(Charmaine S. Tam et al. 2012; Ohno H. et al. 2012). They express low levels of UCP1 in 
comparison to classic brown adipocytes but can be highly inducible in response to appropriate 
stimuli as mentioned, allowing increasing energy expenditure by the thermogenic mechanism of 
UCP1 (Charmaine S. Tam et al. 2012). The mechanisms regarding the browning process are 
associated with enhanced expression of transcriptional components that controls the 
development of classical brown adipocytes such as PRD1-BF-1-RIZ1 homologous domain 
containing protein-16 (PRDM16), PGC1α, PPARγ, CCAAT-enhancer binding protein β 
(C/EBPβ) among others (Kajimura S. et al. 2010). Understanding the biological processes 
controlling brown adipocyte activity and differentiation might help to design strategies involving 
transdifferentiation of brown-like adipocytes to increase energy expenditure and therefore, fight 
against obesity and diabetes.  
 
1.3.2. The uncoupling protein UCP1 
 
UCP1 was first discovered and isolated at the end of the seventies (Nicholls DG. et al. 
1978; Lin CS. et al. 1980) and it was further fully characterized in the following decade (Ricquier 
D. et al. 1983; Bouillaud F. et al. 1985; Bouillaud F. et al. 1986). UCP1 has a molecular weight 
that ranges between 32 and 33 kDa and it was first referred as thermogenin before the discovery 
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of others UCPs. But despite being a member of the UCP superfamily, which also includes 
UCP2, UCP3, UCP4, UCP5 brain mitochondrial carrier protein 1 (BMCP1), UCP1 evolved to 
be the only UCP with a recognized thermogenic capacity (Richard D., Picard F. 2011). 
Functionally, when activated, UCP-1 causes a leak of the electrochemical proton gradient 
that is generated by the respiratory chain and hence, uncoupling the mitochondrial respiration 
from ATP synthesis (Richard D., Picard F. 2011). UCP1 then enables the re-entry of protons to 
the mitochondrial matrix and, as a consequence, energy liberated from substrate oxidation is 
dissipated as heat (figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Molecular mechanism implicated in termogenesis. The electron transport chain produces a 
proton flux into the intermembrane space through the mitochondrial inner membrane. These protons 
can re-entry to the mitochondrial matrix by the ATP synthase, thus producing ATP (A), or alternatively, 
can cross the mitochondrial inner membrane by UCP1 proteins, leading to production of heat (B).   
(Adapted from Richard D., Picard F. 2011)  
(A) 
(B) 
22 
 
1.4. Immunosupressors and mitochondrial function 
 
Mitochondria plays an essential role in the viability of eukaryotic cells producing its 
energy for the different metabolic functions and IAs are known to disturb these functions. 
However, the effects of these agents on mitochondrial respiration and function are not well 
known and should be further investigated.  
Indeed, it is known that mitochondria activity is more sensitive to glucose in the presence 
of the hormone steroid dexamethasone in pancreatic islets of rats, resulting in increased 
NAD(P)H production which affects KATP channel activity leading to insulin hypersecretion 
(Rafacho A. et al. 2010).  
Mitochondria is an organelle that plays important roles regarding the life time of a cell by 
many different ways, imposing its mechanisms of cell death, cell cycle and cell growth. One of 
the mechanisms of cell death is by the mitochondrial permeability transition pore (PTP), which is 
a mitochondrial channel involved in cell death when it stays open for long periods of time 
(Lablanche S. et al. 2011). PTP is also involved in important mechanisms that trigger the 
oscillatory activity of the beta-cells (Düfer M. et al 2001). This pore is inhibited by the 
immunosuppressor CsA and a study performed in pancreatic islet cells of fed female NMRI mice 
showed that CsA acts on PTP, inhibiting the oscillations in the electrical potential (Düfer M. et al 
2001). These results are accompanied by the reduction of the cytoplasmatic free-Ca2+ leading to 
reduced insulin secretion which is independent of calcineurin inhibition (Düfer M. et al 2001). 
It has been shown that inhibition of mTOR with rapamycin enhances autophagy in adipocytes 
from patients with T2D (Ost A. et al. 2010). This study has shown that the inhibition of mTOR 
signaling can potentiate autophagy at the level of mitochondria in adipose tissue of these 
patients, which may be the basis of some of the adverse effects in mTOR inhibition (Ost A. et al. 
2010). 
Glucose-induced insulin secretion from beta-cells is often impaired due to the reduced 
glucose-induced ATP elevation by exposure to high metabolic fuels and after exposure to 
diabetogenic pharmacological agents (Fujimoto S. et al 2007). In pancreatic beta-cells, 
mitochondrial ATP production via glycolysis results from the entry of glucose in cells which is 
fundamental for the mechanism of insulin secretion (Maechler P. et al. 2001). Thus, experiments 
performed in pancreatic beta-cells on Wistar rats exposed to chronic rapamycin exhibited 
reduced mitochondrial ATP production compared to controls. However immunoblotting assays 
revealed that rapamycin did not affect expression of complex I, III, IV and V of the 
mitochondrial respiratory chain proteins (Shimodahira M. et al. 2010). These observations show 
that rapamycin suppresses high glucose-induced insulin secretion on pancreatic islets, and the 
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process involved is believed to be due by the reduction of mitochondrial ATP production 
through decreased alpha-ketaglutarate activity that limits the velocity of carbohydrate metabolism 
in the Krebs cycle (Shimodahira M. et al. 2010). 
Further information is needed to clarify the role of the diabetogenic pharmacological 
agents, such as immunosuppressors in insulin signaling and in mitochondrial function on the 
different insulin target tissues. 
 
 
 
II. Aims of study 
a) To investigate the effect of IAs on the insulin signaling cascade in differentiated brown 
adipocytes. 
 
b) To verify whether or not IAs inhibits GLUT4 translocation and glucose uptake in 
insulin-stimulated differentiated brown adipocytes. 
 
c) To verify the effect of IAs on the mRNA levels of UCP1 and PGC1α in differentiated 
brown adipocytes after stimulation or not with norepinephrine. 
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III. Materials and Methods 
 
1. Materials 
     1.1. Reagents 
 Fetal bovine serum (FBS), Medium 199, Dulbecco's Modified Eagle Medium (DMEM), 
0.25% Trypsin-0.02% EDTA, and Trizol were from Gibco Life Technologies, Gaithersburg, 
MD, USA (www.invitrogen.com). 
 Insulin, penicillin, streptomycin, FK506, norepinephrine, dimethyl sulfoxide (DMSO) and 
Tris were from Sigma-Aldrich, St Louis, MO, USA (www.sigma-aldrich.com). 
 Leupeptin, and aprotinin were from Roche Molecular Biochemicals, Barcelona, Spain 
(www.roche-applied-science.com). 
 Reagents for protein electrophoresis were from Bio-Rad, Hercules, CA, USA (www.bio-
rad.com). 
 Rapamycin was from Santa Cruz Biotechnology (www.sbtc.com) 
 CsA was from EMD Millipore chemicals (http://www.emdmillipore.com) 
 
1.2. Table 1.  Primary antibodies 
 
Antibody Provenance Reference 
Anti-PKB/Akt 
Cell signalling technology 
(MA, USA) 
#9272 
Anti-phospho JNK Cell signalling technology #4668 
Anti-JNK Santa Cruz sc-571 
Anti-phospho 
PKB/Akt1/2/3 (Ser 308) 
Santa Cruz Sc-16646-R 
Anti-phospho 
PKB/Akt1/2/3 (Ser 473) 
Santa Cruz Sc-7985-R 
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Anti-FAS BD F72520 
Anti-IRS-1 Upstate (Millipore) 06-248 
Anti-P85α Upstate (Millipore) 06-195 
Anti phospho IRS-1 Ser 307 Upstate (Millipore) 07-844 
Anti Insulin Receptor (IR) Santa Cruz sc-711 
Anti phospho IR 
(Ty1162/1163) 
Santa Cruz sc-25103-R 
Anti-phospho p70S6K Cell signalling  9202 
Anti-tubulin Sigma T5168 
Anti-phospho ERK 1/2 (Thr 
177/160) 
Santa Cruz sc-23759-R 
Anti-PGC1α Cayman Chemical 101707 
Anti-UCP1 Abcam Ab10983 
 
 
2. Cellular culture 
 
2.1. Generation of brown adipocyte cell line 
2.1.1. Primary cultures of brown adipocytes 
Precursor cells were obtained from the interscapular BAT of 20-day-old rats (Sprague-
Dawley), isolated as previously described by Néchad et al. (1983), by collagenase digestion 
(0·2%) and filtration through 250 µm silk filters. Mature cells were allowed to float, and the 
infranatant was put through 25 µm silk filters and centrifuged. Precursor cells were seeded at a 
density of 1500–2000 cells/cm2 on day 1, and grown in DMEM supplemented with 10% FBS, 3 
nM insulin, 10 mM HEPES, 50 IU penicillin and 50 µg streptomycin/ml, and 15 µM ascorbic 
acid. Culture medium was changed on day 1 and every second day thereafter. Precursor cells 
proliferate actively under these conditions, reach confluence at day 4 or 5 after seeding (40 000–
26 
 
60 000 cells/cm2) and differentiate spontaneously into mature brown adipocytes. All studies and 
treatments were performed in fully differentiated brown adipocytes (at days 8–9 after seeding). 
 
2.1.2. Immortalization of primary brown adipocytes  
Brown adipocytes were obtained from interscapular brown adipose tissue of 20 day-old 
lactating Wistar rats. Cells were plated in 6-well multiwall tissue culture plates in DMEM 
supplemented with 20% FBS, 25 mmol/l glucose, 20 mmol/l HEPES, and 100 U/ml 
penicillin/streptomycin to allow cell attachment and growth to 80% confluence. Retroviral 
infection with large T antigen particles was performed accordingly with the protocol set up in the 
laboratory of Dr AM Valverde and detailed in Valverde et al., 1999. 
 
2.1.3. Differentiation of immortalized brown adipocytes 
Immortalized brown preadipocytes were grown in DMEM supplemented with 10% FBS, 
20 nM insulin and 1 nM triiodothyronine (T3) (differentiation medium) until reaching confluence 
as describe by Miranda S. et al. (2010). Then, the cells were cultured for 48 hours in induction 
medium consisting of differentiation medium supplemented with 0.5 µM dexamethasone, 0.125 
µM indomethacin and 0.5 mM isobutylmethylxanthine. Thereafter, cells were cultured back in 
differentiation medium until they exhibited a fully differentiated phenotype (≈ day 8) with 
numerous multilocular lipid droplets in the cytoplasm. Differentiation medium was renewed 
each 48 hours (Miranda S. et al. 2010).  
 
2.2. Cell treatments  
Cells were treated with CsA, FK506 or rapamycin using three dose ranges, the highest 
dose is considered a therapeutic concentration, in the clinic. Cells were treated with the 
respective IA during different times, depending on the aim of the experiment but mostly, cells 
were treated for 24 hours. Then, for analysis of insulin signaling and glucose uptake, cells were 
serum-starved for 1 hour followed by stimulation with insulin (10 nM) for 10 minutes. In 
another experiments, cells were further stimulated with norepinephrine (5 µM) for 8 or 16 hours.   
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2.3. Preparation of total cell lysates 
At the end of each experiment, the cells were firstly washed twice in PBS, and then 
collected in lysis buffer containing 10 mM Tris-HCl, 5 mM EDTA, 50 mM NaCl, 30 mM 
disodium pyrophosphate, 50 mM NaF, 100 µM Na3VO4, 1% Triton X-100, 1 mM 
phenylmethylsulfonylfluoride, 10 µg/ml leupeptin and 10 µg/ml aprotinin pH 7.6.  
 
3.    Analysis of Protein Expression:    
 3.1. Protein Extracts: 
After harvesting brown adipocytes with lysis buffer, homogenates were stored at -20ºC 
or used immediately to prepare protein extract. For this goal, homogenates were centrifuged 
twice at 11.200 x g for 7 minutes, first to discard the pellet and second to discard lipids on the 
surface of the supernatant. 
 
3.2. Protein Quantification 
Protein quantification was performed by the Bradford dye method in duplicate, using the 
Bio-Rad reagent and BSA to prepare the standard curve. 
 
3.3. Western blotting  
Western Blot (WB) analyses were used to determine proteins levels and phosphorylation 
of some mediators of the insulin signaling cascade in brown adipocyte lysates, allowing us to 
collect information about the expression of proteins as well as their activation levels. 
Equal amount of protein (15 µg or 25 µg), mixed with 4x loading buffer (for a final 
concentration of 1x) were heated at 95ºC for 5 minutes. Then, total protein extracts were 
resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to polyvinylidene fluoride (PVDF) transfer membranes. 
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3.4. Protein Transfer 
PVDF membranes (Immobilon P, Millipore), were firstly activated for 1 minute in 
methanol and then washed in distilled water for 5-7 minutes to remove the excess of methanol. 
Membranes were then maintained wet in transfer buffer until the preparation of the cassette and 
transfer equipment. Protein transfer conditions used were: 300 mA for 2 hours or 100 V for 1 
hour. 
 
3.5. Antibody staining 
 
Membranes were blocked for 1 hour at room temperature or overnight at 4°C using 
blocking solution (3% bovine serum albumin (BSA)). Then, the membranes were incubated with 
appropriate dilutions of primary antibody in Tris-Buffered Saline and 0.05% Tween-20 (TTBS) 
overnight at 4°C or for 2 hours at room temperature. The membranes were washed four times 
with TTBS (10 minutes each). Then, the membranes were incubated with the recommended 
dilution of labelled secondary antibody in TTBS at room temperature for 1 hour with either 
alkaline phosphatase-conjugated anti-rabbit antibody (1:15000), alkaline phosphatase-conjugated 
anti-mouse antibody (1:15000) or alkaline phosphatase-conjugated anti-goat antibody (1:15000). 
The membranes were washed three times with TTBS (10 minutes each) and a final wash with 
TBS without Tween-20 for additional 10 minutes. Immunoreactive proteins were visualized by 
chemiluminescence using the ECL western blotting protocol (Millipore) and Agfa radiographic 
films. 
 
4. Analysis of gene expression by Quantitative Real-time PCR 
Total RNA extraction from brown adipocytes was performed with Trizol. 
Complementary DNA (cDNA) was synthesized by reverse transcription PCR (RT-PCR) from 1 
μg of RNA using iScript cDNA synthesis kit (BioRad, Hercules, CA). For qPCR, each cDNA 
sample was run in an ABI 7300 in triplicate well, in the following PCR program: 50 °C for 2 
minutes, 94 °C for 10 minutes, and 30 cycles of 97 °C for 30 s followed by 60 °C for 1 minute . 
UCP-1 mRNA was quantified using specific FAMTM dye-labeled TaqMan® probes for UCP-1 
(Rn00562126-m1; Gene expression assays, Applied Biosystems, Foster City, CA) and PGC1α 
(Rn00580241_m1; Gene expression assays, Applied Biosystems, Foster City, CA). Results were 
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normalized using VIC® dye-labeled TaqMan® probe for ubiquitin (Rn01789812-g1, Applied 
Biosystems). 
 
5. Measurement of glucose transport 
At the end of the incubation without or with compounds, differenciated brown 
adipocytes were serum-deprived for 2 hours. After that, cells were washed three times with ice-
cold Krebs-Ringer-phosphate buffer (KRP) (135 mM NaCl, 5.4 mM KCl, 1.4 mM CaCl2, 1.4 
mM MgSO and 10 mM sodium pyrophosphate, pH 7.4) and then incubated with 1 ml KRP 
buffer with or without insulin for 10 minutes at 37ºC. 2-Deoxy-D[1-3H]glucose (500 nCi/ml) 
was added to this solution, and the incubation was continued for 5 minutes at 37º C. The cells 
were then washed three times with ice-cold KRP buffer and solubilized in 1 ml 1% SDS, as 
previously described (Valverde, AM. et al 1998). The radioactivity of a 200-µl aliquot was 
determined in a scintillation counter. Glucose transport was determined in triplicate from three 
independent experiments. 
 
6. Oxygen Consumption 
An XF24 Seahorse Bioscience (North Billerica, MA, USA) instrument was used to 
measure the oxygen consumption rate (OCR) of differentiated brown adipocytes at days 7-8 of 
differentiation. DMEM growth media was replaced by unbuffered DMEM supplemented with 
25 mM glucose, 1 mM pyruvate and 2 mM L-glutamine and cells incubated at 37 °C in a CO2-
free incubator for 1 h. Cells were then placed in the instrument and basal oxygen consumption 
was recorded for 24 minutes and subsequently 1 μg/ml oligomycin and 400 nM FCCP were 
added. At the end of the run, 1 μM rotenone and 1 μM antimycin A were added to determine 
the mitochondria-independent oxygen consumption according to Ortega-Molina et al. (2012). 
 
7. Immunofluorescence and confocal imaging 
 
 Cells were grown on glass coverslips, fixed in 4% paraformaldehyde and processed for 
immunofluorescence. Briefly, anti-GLUT4 (sc-56566, Santa Cruz) primary antibody was applied 
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for 1 h at 37ºC in PBS-1% BSA at 1/50 dilution. The secondary antibody used was Alexa 488 
goat anti-mouse (Invitrogen) at 1/500 dilution. Cell nuclei were counterstained with DAPI 
(Sigma). Immunofluorescence was examined in a Nikon Eclipse 90i microscope with imaging 
software Nis elements.   
 
 
8. Statistical analysis 
Results are given as mean ± standard error of the mean (SEM) using GraphPad Prism, 
version 5 (GraphPad Software, San Diego, CA, USA). Statistical analyses using the Student’s t-
test were performed when two groups were considered. For multiple group comparisons, the 
One-Way ANOVA test, followed by the post hoc Bonferroni´s Multiple Comparison was used. 
Differences were considered significant when *p < 0.05 or **p < 0.01 
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IV. Results 
 
Effect of rapamycin treatment in the insulin signaling cascade in differentiated brown 
adipocytes 
For the studies of the impact of IAs on insulin-mediated signaling, we used an 
immortalized rat preadipocyte cell line generated in the laboratories of Drs AM Valverde and MJ 
Obregón (CSIC, Madrid, Spain) as detailed in Materials and Methods. Brown preadipocytes were 
seeded in 12 well plastic culture plates and differentiated as described in Materials and Methods. 
At day 8, we observed that have reached a fully differentiated phenotype as shown by the 
accumulation of multilocular lipid droplets as well as by the expression of the adipogenic marker 
fatty acid synthase (FAS) and the thermogenic marker UCP1 (Figure 1A) that assessed terminal 
differentiation of brown fat cells. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1. Upper panel. Images of  immortalized brown preadipocytes generated from lactating rats (left) and 
differentiated brown adipocytes at day 8 (right). Lower panel. Expression of FAS and UCP1 in differentiated brown 
adipocytes analyzed by western blot with specific antibodies. B  Expression of insulin receptor substrate 1 (IRS-
1), insulin receptor (IR) and phospho p70S6 kinase in immortalized rat brown adipocytes at day 8 of 
differentiation exposed for 16 h to increasing doses of rapamycin (Rap) and stimulated 10 min with 10 nM insulin. 
Representative western blot of three independent experiments are shown. 
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We proposed to investigate total levels of IRS-1 in differentiated brown adipocytes 
treated with various doses of rapamycin (10-100 nM) for 16 hours because it has been previously 
reported that IRS-1 is a critical node of the insulin signaling cascade in brown adipocytes and 
since its deficiency in mice inhibits the signaling pathway that leads to adipogenic and 
thermogenic gene expression (Valverde AM. et al., 1999; Valverde AM. et al 2003). As shown in 
Figure 1B, IRS-1 levels decrease in brown adipocytes incubated with rapamycin in a dose-
dependent manner. Notably at 100 nM dose of rapamycin, IRS-1 was barely detected whereas 
the expression of the IR beta chain remained unchanged regardless rapamycin treatment. The 
efficacy of rapamycin treatment was assessed by the complete inhibition of the phosphorylation 
of the mTOR substrate p70S6K1 in insulin-stimulated cells as compared with cells that were not 
pretreated with this compound. 
We next investigated the effect of rapamycin in insulin signaling towards the activation of 
PKB/Akt that has been shown to regulate adipogenic- and thermogenic-related gene expression 
downstream from IR and IRS-1 in brown adipocytes (Valverde AM. et al., 1999; Fasshauer M et 
al., 2001, Valverde AM. et al., 2003). Pretreatment of brown adipocytes with rapamycin did not 
modulate tyrosine phosphorylation of the IR upon insulin stimulation (Figure 2). However, 
rapamycin decreased insulin-induced PKB/Akt phosphorylation at both serine 473 (within the 
regulatory domain) and threonine 308 (within catalytic domain) residues in a dose-dependent 
manner.  
 
 
 
 
 
 
 
 
 
 
Figure 2. Immortalized brown adipocytes from rat were treated with rapamycin (at different doses) for 16h, and 
then cells were serum-starved for 1 h followed by stimulation with insulin (10 nM) for 10 min. Thereafter, cells 
were collected in lysis buffer. Phosphorylation of insulin receptor (IR) and PKB/Akt at serine 473 and threonine 
308 were analyzed by western blot as well total levels of IR and Akt. Representative western blots of three 
independent experiments are shown. Abbreviations: Rap (rapamycin), ins (insulin). 
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Once defined the impact of rapamycin pretreatment in insulin-mediated IRS-1/Akt 
signaling pathway in brown adipocytes, we analyzed the effect of CsA and FK506. For this goal, 
differentiated brown adipocytes (day 8) were pretreated with several doses of CsA or FK506 for 
16 hours, after that cells were stimulated with 10 nM insulin for a further 10 minutes. CsA 
pretreatment didn’t decreased IR-mediated tyrosine phosphorylation, but decreased total IRS-1 
levels (Figure 3A). Consequently, phosphorylation of PKB/Akt at both serine 473 and threonine 
308 residues was severely impaired. Similarly, FK506 did not affect IR tyrosine phosphorylation 
in response to insulin. Regarding total IRS-1, FK506 didn’t decrease IRS-1 total protein. 
However, as occurred with the other IAs, FK506 impaired insulin-stimulated Akt 
phosphorylation (Figure 3B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Immortalized brown adipocytes from rat were treated with CsA (A) and FK506 (B) at different 
doses for 16h, and then cells were serum-starved for 1 h followed by stimulation with insulin (10 nM) for 10 
min. Thereafter, cells were collected in lysis buffer. Expression of insulin receptor substrate 1 (IRS-1), 
phosphorylation of insulin receptor (IR) and PKB/Akt were analyzed by western blot as well as total IR and 
total Akt. Representative western blots of three independent experiments are shown. are shown. Abbreviations: 
CsA (cyclosporine A), FK (tacrolimus), ins (insulin). 
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To confirm that the effect of IAs on insulin signaling in brown adipocytes was not due to 
immortalization and/or the differentiation protocol, we prepared primary brown adipocytes 
from 20 days-old lactating rats as described in Materials and Methods (2.2) and allowed them to 
differentiate expontaneously during 10 days. As shown in Figure 4, when differentiated primary 
brown adipocytes were pretreated during 16 hours with 100 nM dose of rapamycin, CsA or 
FK506 and then stimulated with insulin, the impairment of insulin-mediated PKB/Akt 
phosphorylation was observed as in the immortalized cell line. 
 
 
 
 
 
 
 
 
Rapamycin rapidly induced the phosphorylation of c-Jun NH(2)-terminal kinase (JNK) 
and IRS-1 at serine 307 (Ser307) 
Activation of stress kinases, particularly JNK, has been shown to inhibit insulin-mediated 
signalling in peripheral tissues by its ability to induce IRS-1 phosphorylation at Ser307, thereby 
functionally uncoupling IRS-1 from the insulin receptor and promoting IRS-1 degradation (Tanti 
and Jagger, 2009). On that basis we analyzed JNK phosphorylation in differentiated brown 
adipocytes treated with the different IAs. In initial experiments we treated differentiated brown 
adipocytes with 100 nM of rapamycin, CsA or FK506 for 1 hour. At this time-period only 
rapamycin was able to induce JNK phosphorylation as compared to non-stimulated cells (Figure 
5A). However, increased phosphorylation of p38 MAPK, also belonging to the stress kinase 
family, was not observed in IAs-treated cells. Next, we analyzed the response of brown 
adipocytes to rapamycin or CsA in a more detailed time-course experiment. Results shown in 
Figure 5B indicate that the response to rapamycin in inducing JNK phosphorylation was very 
Figure 4. Differenciated brown adipocytes from rat primary culture were treated with IAs (1 µM CsA and FK 
and 100 nM for Rap) for 16 h, and then cells were serum-starved for 1h followed by stimulation with insulin 
(10nM) for 10min. Thereafter, cells were collected in lysis buffer. Representative western blots using antibodies 
against Akt (serine 473 and threonine 308) and total IR as protein loading control are shown. Abbreviations: Ctrl 
(control), CsA (cyclosporine A), FK (tacrolimus), Rap (rapamycin), ins (insulin). 
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rapid, with a maximal effect at 30 minutes. JNK phosphorylation was maintained up to 2 hours 
of rapamycin stimulation. Importantly, total levels of JNK remained as in control cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
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Figure 5. A) Differenciated brown adipocytes from rat (immortalized cells) were treated with IAs (100nM) for 
1h. Thereafter, cells were collected in lysis buffer. Representative western blots using antibodies against phospho-
JNK, total JNK and phospho-p38 MAPK of three independent experiments are shown. B) Differenciated brown 
adipocytes from rat (immortalized cells) were treated with Rap (100 nM) during different periods of time until 4 
h. Representative western blots using phospho-JNK and total JNK are shown. C) Cells were stimulated as 
describe in B and treated with CsA (100 nM). Representative western blots using antibodies against phopho-IRS-
1 (Ser307) and total IRS-1 are shown. Abbreviations: Ctrl (control), CsA (cyclosporine A), FK (tacrolimus), Rap 
(rapamycin). 
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To inspect if rapamycin-mediated JNK phosphorylation was able to phosphorylate IRS-1 
at serine residues, we performed western blot analysis with the phospho-specific anti-IRS-1 
Ser307 antibody. In agreement with JNK phosphorylation, treatment of differentiated brown 
adipocytes with rapamycin induced IRS-1 Ser phosphorylation within similar time-periods (30 
minutes-2 hours) (Figure 5B). Besides, total levels of IRS-1 remained unchanged along the 
experiment.  
  Since CsA also decreased IRS-1 levels, we performed similar time-course with this 
compound. As shown in Figure 5C, CsA also increased IRS-1 Ser307 phosphorylation. Although 
CsA did not increase JNK phosphorylation as shown in Figure 5A, it increased ERK 
phosphorylation at very early time-periods (15-30 min), time at which IRS-1 Ser307 
phosphorylation was detected.  
 
Effect of IAs on insulin-induced glucose uptake and GLUT4 translocation in 
differentiated brown adipocytes 
In primary fetal brown adipocytes, insulin induced glucose uptake in a PI 3-kinase-
dependent manner (Valverde AM. et al., 1998). Therefore, we assayed the response to insulin in 
inducing glucose uptake in our in vitro cellular model of immortalized brown adipocytes upon 
differentiation. For this goal, differentiated brown adipocytes (day 8) were pretreatred with 100 
nM rapamycin, CsA or FK506 for 16 h and glucose uptake was analyzed after insulin stimulation 
for 10 minutes as described in Materials and Methods. Figure 6A shows that differentiated 
brown adipocytes from rat responded to insulin in inducing glucose uptake with a threefold 
increase above the controls. Interestingly, this response was significantly decreased in cells that 
had been pretreated with IAs. These results were confirmed by the analysis of GLUT4 
translocation by immunofluorescence. As shown is figure 6B, insulin-induced a rapid 
accumulation of GLUT4 in the plasma membrane in differentiated brown adipocytes whereas 
GLUT4 was accumulated in internal compartments in non-treated cells. By contrast, in 
differentiated brown adipocytes treated with IAs GLUT4 immunofluorescence was barely 
observed in the plasma membrane. 
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Figure 6.  Brown adipocytes were differentiated for 8 days and treated with IAs (100 nM) for 16h. Then cells 
were serum-starved for 1 h followed by stimulation with insulin (100 nM) for 10min. Thereafter, glucose uptake 
was analyzed as described in Materials and Methods. Results are expressed in cpm/min/µg protein; *p<0.05, 
**p<0.01 IAs-treated insulin stimulated cells vs insulin stimulated cells (non-treated with IAs). Abbreviations: Ctrl 
(control), CsA (cyclosporine A), FK (tacrolimus), Rap (rapamycin), ins (insulin). 
* * 
** 
- + - + - + - + 
CsA FK Rap Ctrl 
ins (10nM)  
Ctrl Ins 
CsA+ins FK506+ins Rap+ins 
Figure 7.  Brown adipocytes were differentiated for 8 days and treated with IAs (100 nM) for 16h. Then cells were 
serum-starved for 1 h followed by stimulation with insulin (100 nM) for 10min. Thereafter, Immunofluorescence 
and confocal imaging was analyzed as described in Materials and Methods. Immunofluorescence analysis of GLUT4 
translocation were performed using anti-GLUT4 antibody. Nuclei were stained with DAPI. Representative images 
of two independent experiments are shown. Abbreviations: Ctrl (control), CsA (cyclosporine A), FK (tacrolimus), Rap 
(rapamycin), ins (insulin). Scale bar shows 60 µm. 
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Rapamycin decreased the response of differentiated brown adipocytes to norepinephrine 
(NE) in the induction of Pgc1a and Ucp1 mRNA levels 
It has been shown that NE stimulates Pgc1a and Ucp1 mRNA levels in primary rat brown 
adipocytes (Cao W et al., 2004; Hernandez et al., 2011). Thus, we determined the effect of CsA, 
FK506 and rapamycin on thermogenesis by measuring Pgc1a and Ucp1 mRNA in our in vitro 
cellular model of immortalized brown adipocytes upon differentiation. For this goal, brown 
adipocytes at day 8 of differentiation were cultured in differentiation medium supplemented with 
CsA or FK506 or rapamycin, each at 100 nM concentration during 24 hours. Then, NE (5 µM) 
was added directly to the culture plates for a further 16 hours. As shown in the Figures 8A and 
8B, treatment with NE induced about 30-fold increases in Ucp1 mRNA over basal levels and that 
induction was completely blunted by treatment with rapamycin. On the contrary, treatments with 
CsA and specially FK506 further induced Ucp1 mRNA expression (2- and 3.5-fold). CsA and 
FK506 also increased in similar proportions the basal Ucp1 mRNA expression, while rapamycin 
had no effect on basal Ucp1 mRNA (Figure.  8C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Brown adipocytes were differentiated for 8 days. 
Then, CsA, FK and Rap were added during 24 h and NE 
(5 µM) was added for a further 16 h to half of the culture 
plates. Cells were collected in Trizol to isolate RNA. For 
qPCR, Ucp1 Taqman probe was labeled with FAM and 
Ubq was labeled with VIC and used as endogenous control. 
A) Two independent experiments are shown. B) Results 
are referred as percentage of increase (CsA and FK) or 
decrease (Rap) with respect to values obtained with NE. 
C) Results are referred as fold of increase (CsA and FK) or 
decrease (Rap) with respect to basal values (absence of 
NE). Results are given as mean ± standard error of the 
mean (SEM).  Statistical significance is shown in each 
panel. Abbreviations: NE (norepinephrine), CsA 
(cyclosporine A), FK (tacrolimus), Rap (rapamycin).  
 
 
(A) (B) 
(C) 
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Pgc1α was also determined using the same protocol of treatments. Similarly to the 
changes in Ucp1 mRNA, the basal expression of Pgc1α mRNA was increased when using CsA 
and FK506 (2.5 and 3.5-fold, respectively), while no effect was observed with rapamycin (Figures 
9A and 9B). As expected, treatment with NE increased Pgc1α mRNA by 3.4 fold over basal and 
such increases were further increased by CsA or FK506 pretreatments and decreased by 
rapamycin to basal values (Figure 9C). Therefore, the pattern of changes in Pgc1α mRNA was 
similar to that found in Ucp1 mRNA. 
At present, we are setting experiments with the Seahorse technology (see Materials and 
Methods) in order to get more insights on the effect of IAs on mitochondrial respiration in 
brown adipocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
Figure 9 Brown adipocytes were differentiated for 8 days. Then, CsA, FK and Rap were added during 24 h and NE (5 µM) 
was added for a further 16 h to half of the culture plates. Cells were collected in Trizol to isolate RNA. For qPCR, Ucp1 
Taqman probe was labeled with FAM and Ubq was labeled with VIC and used as endogenous control. A) Two independent 
experiments are shown. B) Results are referred as percentage of increase (CsA and FK) or decrease (Rap) with respect to 
values obtained with NE. C) Results are referred as fold of increase (CsA and FK) or decrease (Rap) with respect to basal 
values (absence of NE). Results are given as mean ± standard error of the mean (SEM).  Statistical significance is shown in 
each panel. Abbreviations: NE (norepinephrine), CsA (cyclosporine A), FK (tacrolimus), Rap (rapamycin).  
 
 
 
 
(C) 
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V. Discussion 
 
In rodents, glucose is an important fuel for BAT in vivo. Under physiological insulin 
stimulation, BAT has an extremely high rate of glucose metabolism (10% of the total glucose 
turnover rate in the rat), and a number of metabolic genes are induced. Among them, insulin 
plays an important role in the regulation of UCP1 expression in vivo. Indeed, the maintenance of 
normal concentrations of UCP1 in BAT has been shown to require normal plasma insulin levels. 
Conversely, insulin resistance in BAT appears in different physiological situations such as 
pregnancy, lactation and obesity ((Ferre et al. 1986, Lorenzo et al., 2005). All together these data 
identify the role of BAT in the overall control of glucose homeostasis. The importance in 
maintaining functional insulin signaling in BAT for the control of whole body glucose 
homeostasis was evidenced in mice with specific deficiency of IR in BAT (BATIRKO) that 
showed glucose intolerance due to a defect in insulin secretion (Guerra et al., 2001). Taking into 
account these findings, our results have demonstrated for the first time that brown adipocytes 
are target cells for immunosuppressant action, particularly by their ability to interfere with insulin 
signaling, suggesting that insulin resistance in BAT might contribute to PTDM.  
The first evidence of this negative cross-talk between IAs and insulin signaling in 
differentiated brown adipocytes was the decrease in total IRS-1 levels upon long-term (16 h) 
treatment with rapamycin and CsA. During the last years, the IRS proteins have emerged as 
critical regulators of upstream signaling pathways leading to brown adipocyte differentiation. 
Particularly, IRS-1 deficiency totally impairs brown adipocyte differentiation (Fasshauer et al., 
2001).  IRS-1 is also necessary for full UCP1 expression in differentiated brown adipocytes 
(Tseng et al., 2004) and for its induction in response to insulin in brown preadipocytes (Valverde 
et al., 2003). Therefore, the fact that IRS-1 levels were decreased by rapamycin or CsA treatment 
prompted us to hypothesize that insulin signaling downstream IRS-1 that lead to metabolic 
actions of this hormone could be impaired. Not surprisingly, PKB/Akt phosphorylation at both 
Ser473 and Thr308 residues was blunted when insulin-stimulated brown adipocytes were 
pretreated with CsA, rapamycin and also FK506. While this impaired response is directly related 
with IRS-1 degradation by CsA or rapamycin, the effect of FK506 in blunting PKB/Akt 
phosphorylation is independent of defects in upstream insulin signaling. Besides, all three 
compounds significantly reduced insulin-induced GLUT4 translocation and glucose uptake that 
has been extensively demonstrated to be dependent on PKB/Akt (Huang and Czech, 2007). Our 
results are in agreement with previous findings in human white adipocytes showing impaired 
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insulin-induced glucose uptake and GLUT4 translocation upon pretreatment with IAs (Pereira 
MJ et al., 2012; Lopes P et al., 2013). However, slight differences have been found between the 
two types of adipocytes regarding insulin signaling. Whereas both calcineurin inhibitors did not 
affect PKB/Akt phosphorylation in white fat cells (Pereira MJ, unpublish results), both 
compounds blunted this response in brown adipocytes. These results suggest that activation of 
Akt/PKB is essential for mediating glucose uptake and GLUT4 translocation exclusively in 
brown adipocytes and, as suggested by Pereira MJ, CsA and FK506 do not allow translocation of 
GLUT4 to the cell surface of white adipocytes, as well as in L6 muscle cells, by increasing the 
rate constant for endocytosis. However, we cannot exclude the possibility of alterations in 
GLUT4 trafficking in brown fat cells treated with calcineurin inhibitors. On the other hand, 
rapamycin decreased PKB/Akt phosphorylation in both types of adipocytes (Pereira MJ et al., 
2012 and our results) but with different responses in the levels of IRS proteins. Whereas 
rapamycin decreased IRS2 levels in subcutaneous human adipocytes, it decreased IRS-1 in brown 
adipocytes. Thus, altogether these results suggest different susceptibility of rapamycin-mediated 
IRS-1 and IRS2 degradation in different adipose cell types. This interesting issue deserves further 
investigations. 
Phosphorylation of IRS-1 upon serine 307 has been shown to negatively regulate insulin 
signal transduction. Phosphorylation of serine 307 inhibits insulin-stimulated tyrosine 
phosphorylation and IRS-1-associated PI-3 kinase activity, potentially through disruption of the 
protein–protein interaction between IRS-1 and the IR. Serine 307 phosphorylation can be 
induced by cellular stressors, insulin, TNF-α and lipids, all factors that cause insulin resistance 
(reviewed by Copps and White MF, 2012). Several lines of evidence support a central role for 
mTOR in the development of insulin resistance and regulating the phosphorylation of IRS-1 
serine 307. In this regard, rapamycin has been shown to prevent the development of insulin 
resistance and the degradation of IRS-1, likely through the inhibition of serine phosphorylation 
(Sun XJ et al, 1999; Pederson T et al., 2001; Berg CE et al., 2002). In agreement with these 
studies, rapamycin prevented IRS-1 serine 307 phosphorylation in human subcutaneous 
adipocytes (Pereira MJ et al., 2012). As stated above, our data in brown adipocytes clearly 
demonstrated that long-term (16 h) rapamycin treatment in differentiated brown adipocytes 
results in IRS-1 degradation that, importantly, is preceded by serine 307 phosphorylation at early 
time-periods (30 min-2 h). Collectively, our results in brown fat cells suggest that in addition to 
mTORC1, other/s serine/threonine kinases might be involved in this negative feed-back 
mechanism.  
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Anisomycin, a potent cellular stressor, downregulates IRS tyrosine phosphorylation in 
CHO cells, which is dependent on the presence of both serine 307 and the IRS-1 
phosphotyrosine binding domain (Aguirre V et al., 2000). Although several kinases are activated 
by anisomycin, JNK1 directly binds to IRS-1. Moreover, JNK is activated by similar triggers that 
activate mTORC1 including hiperinsulinemia, nutrient overloading and oxidative stress (Aguirre 
et al., 2000; Copps and White, 2012). Importantly, we found that in brown adipocytes rapamycin 
rapidly induced JNK phosphorylation and this response was paralleled with IRS-1 serine 307 
phosphorylation. Therefore in addition to the direct inactivation of the mTORC1 complex, 
rapamycin might increase oxidative stress leading to an increase in reactive oxygen species (ROS) 
that activate JNK which, in turn, phosphorylates IRS-1 at serine 307 in an mTORC1-
independent manner. Related to this, very recent findings have shown a mechanism of mTOR 
inactivation by ROS-JNK-p53 pathway that plays an important role in autophagy-dependent 
senescence in L929 cells (Qi et al., Eur J Pharmacol 2013). Of note, neither p38 MAPK nor 
ERK were activated by rapamycin at early time-periods. 
The direct or indirect activation of JNK by rapamycin seem to be specific of this 
compound since it was not observed with CsA or FK506. Of note, treatment of brown 
adipocytes with CsA for 16 hours also led to IRS-1 degradation similar to rapamycin. Similarly, 
CsA induced IRS-1 Ser307 phosphorylation in an early time-course experiment but in the 
absence of JNK phosphorylation. Instead, a rapid activation of ERK was observed, suggesting 
multiple regulatory mechanisms for IAs-mediated insulin resistance in brown adipocytes.  
Additional investigation is necessary to find out other possible modulators involved on such 
effects. 
The effect of the IAs on UCP1 expression was rather different among them, because 
rapamycin had no effect on the basal UCP1 expression, but inhibited the NE-mediated increases 
of UCP1, while CsA and FK506 induced increases in both the basal and NE-stimulated UCP1 
expression, with similar fold increases. We can speculate about the mechanisms that lead to such 
divergent results possibly related to the interference of these drugs on insulin signaling pathways. 
Indeed, in rat primary cultures of brown adipocytes we have observed that the absence of  
insulin or serum as well as the inhibition of PKB/Akt or ERK phosphorylation enhance UCP1 
expression (unpublished results), and it is possible that the increases observed using CsA and 
FK506 could be related to this interference in insulin signaling pathways. On the other hand, the 
inhibitory effect of rapamycin could be related to an effect directly on the cAMP- NE or JNK-
mediated pathways (Cao W et al., 2004).  
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The changes observed in PGC1α are rather parallel to the ones in UCP1, even though at 
a smaller scale. CsA and FK506 increase the basal PGC1α while rapamycin has no effect. PGC1α 
increased with NE, and rapamycin inhibited this increase while FK506 induced a small increase. 
It has been shown that inhibition of mTOR by rapamycin reduces PGC1α gene 
expression in cells and mouse skeletal muscle, as well as reduced mitochondrial activity and 
capacity. The mechanism behind this evidence seems to be mediated through the transcription 
factor yin and yang (YY1), which is known to be a common target of PGC1α and mTOR (Wang 
L. et al., 2011, Cunningham JT.et al., 2007). Thus, regarding PGC1α, the reduced levels of its 
mRNA by rapamycin found in our study in brown adipocytes, could be due to this common 
feature between PGC1α and mTOR. Moreover, it is also known that mitochondrial targets of 
PGC1α involved in oxidative phosphorylation, the tricarboxylic acid  cycle and uncoupling 
respiration are also downregulated by rapamycin (Cunningham JT.et al., 2007), corroborating our 
data that show the inability of NA in inducing UCP1 mRNA in the presence of rapamycin, but 
more information still is needed regarding brown adipose tissue.  
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VI. Concluding remarks  
 
Over the last years, studies performed in BAT have led to a paradigm in our 
understanding of the importance of this unique tissue in adult humans, providing an 
incremented interest in the potential of activating BAT to enhance energy expenditure and 
therefore, fight against obesity and diabetes.  
IAs has been extensively demonstrated to induce PTDM on subjects treated with these 
drugs in order to prevent allograft rejection after organ transplantation. Despite the efforts on 
providing to these patients a good quality of life, further investigation is needed so that, new IAs 
could be produced or the existing ones may be improved, not only for its proper use but also to 
decrease the impact of its side effects. 
For the first time, this study evidenced the negative cross-talk between signaling 
pathways triggered by IAs in brown adipocytes and insulin signaling, being IRS-1 a critical 
modulator. Considering the thermogenic potential of BAT, these data might contribute to 
understand the physiological importance of brown adipocytes on the energy expenditure and its 
influence on insulin resistance in humans. Although in vivo data will reinforce our in vitro studies, 
insulin resistance in BAT might contribute to PTDM. 
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